DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Suzuki, A.
Right arrow Articles by Chiba, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suzuki, A.
Right arrow Articles by Chiba, K.

Vol. 27, Issue 11, 1254-1259, November 1999

Identification of Human Cytochrome P-450 Isoforms Involved in Metabolism of R(+)- and S(-)-Gallopamil: Utility of In Vitro Disappearance Rate

Akio Suzuki, Izumi Iida, Fumie Tanaka, Masayuki Akimoto, Kiyomi Fukushima, Masayoshi Tani, Takashi Ishizaki, and Kan Chiba

Pharmaceutical Research Laboratories, Taisho Pharmaceutical Co., Ltd. (A.S., I.I., F.T., M.A., K.F.), Saitama; Department of Clinical Pharmacology, Research Institute (A.S., I.I., T.I.) and Department of General Surgery (M.T.), International Medical Center of Japan, Tokyo; and Laboratory of Biochemical Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, Chiba University (K.C.), Chiba, Japan

Isoforms of cytochrome P-450 (CYP) involved in the metabolism of gallopamil enantiomers were identified by measuring the disappearance rate of parent drug from an incubation mixture with human liver microsomes and recombinant human CYPs. Mean (± S.D.) intrinsic clearances (CLint) of R(+)- and S(-)-gallopamil in human liver microsomes were 0.320 ± 0.165 and 0.205 ± 0.107 ml/min/mg protein, respectively. These values were highly correlated with the 6beta -hydroxylation activity of testosterone, a marker substrate of CYP3A4 (r = 0.977 and 0.900 for R(+)- and S(-)-gallopamil, respectively, p < .001). Ketoconazole and troleandomycin, selective inhibitors of CYP3A4, and polyclonal antibodies raised against CYP3A4/5 markedly reduced the CLint of gallopamil enantiomers in human liver microsomes. Among the 10 recombinant human CYP isoforms, CYP3A4 exhibited the highest CLint of gallopamil enantiomers, and CYP2C8 and CYP2D6 also exhibited appreciable activity. When the contribution of CYP3A4 to the total metabolic clearance of gallopamil enantiomers in human liver microsomes was estimated by relative activity factor, the mean (± S.D.) contributions were 92 ± 18 and 68 ± 19% for R(+)- and S(-)-gallopamil, respectively. These values were comparable to the rates of immunoinhibition by antibodies raised against CYP3A4/5 observed in human liver microsomes. The present study suggests that CYP3A4 is a major isoform involved in the overall metabolic clearance of gallopamil enantiomers in the human liver, and that the present approach based on disappearance rate may be applicable to identify major isoforms of CYP involved in the metabolism of a drug in human liver microsomes.


Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
S. J. Gardiner and E. J. Begg
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
H. M. Jones and J. B. Houston
SUBSTRATE DEPLETION APPROACH FOR DETERMINING IN VITRO METABOLIC CLEARANCE: TIME DEPENDENCIES IN HEPATOCYTE AND MICROSOMAL INCUBATIONS
Drug Metab. Dispos., September 1, 2004; 32(9): 973 - 982.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Kobayashi, N. Mimura, H. Fujii, H. Minami, Y. Sasaki, N. Shimada, and K. Chiba
Role of Human Cytochrome P450 3A4 in Metabolism of Medroxyprogesterone Acetate
Clin. Cancer Res., August 1, 2000; 6(8): 3297 - 3303.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.